ライフサイエンスコーパス: 5-lipoxygenase

1 olyunsaturated n-6 fatty acid) by the enzyme 5-lipoxygenase.

2 sing pharmacologic and genetic abrogation of 5-lipoxygenase.

3 a novel import sequence at Arg(518) on human 5-lipoxygenase.

4 ability of this class of chelator to inhibit 5-lipoxygenase.

5 nhibitor of CoA-independent transacylase and 5-lipoxygenase.

6 leukocytes is rapidly converted to LTA(4) by 5-lipoxygenase.

7 opentenyl hydroxamic acid-based inhibitor of 5-lipoxygenase.

8 scent protein to the same degree as complete 5-lipoxygenase.

9 ated by activation of phospholipase A(2) and 5-lipoxygenase.

10 unchanged, indicating an abnormality beyond 5-lipoxygenase.

11 levels of NF-kappaB, AKT, ERK1/2, COX-2, and 5-lipoxygenase.

12 ctivity of the iron-containing metalloenzyme 5-lipoxygenase.

13 d in the nucleus, where it co-localizes with 5-lipoxygenase.

14 lear ratio of a key SPM biosynthetic enzyme, 5-lipoxygenase.

15 and its conversion to bioactive lipoxins by 5-lipoxygenase.

16 Arachidonate-5-lipoxygenase (5-LO) activity and increased leukotriene

17 lammatory leukotrienes (LTs) are produced by 5-lipoxygenase (5-LO) aided by 5-LO-activating protein (

18 odel of human asthma to detect lung mRNA for 5-lipoxygenase (5-LO) and 5-LO-activating protein (FLAP)

19 The enzymes 5-lipoxygenase (5-LO) and glycogen synthase kinase (GSK)

20 CSC), but they also suppress the activity of 5-lipoxygenase (5-LO) at clinically feasible concentrati

21 Mammalian 5-lipoxygenase (5-LO) catalyzes conversion of arachidoni

22 Mammalian 5-lipoxygenase (5-LO) catalyzes the conversion of arachi

23 The enzyme 5-lipoxygenase (5-LO) catalyzes the conversion of arachi

24 5-Lipoxygenase (5-LO) catalyzes the rate-limiting step o

25 ety as novel soluble epoxide hydrolase (sEH)/5-lipoxygenase (5-LO) dual inhibitors.

26 The 5-lipoxygenase (5-LO) enzymatic pathway is widely distri

27 The 5-lipoxygenase (5-LO) enzyme is widely distributed withi

28 To initiate LT formation, the 5-lipoxygenase (5-LO) enzyme translocates to nuclear mem

29 Here we identify the arachidonate 5-lipoxygenase (5-LO) gene (Alox5) as a critical regulat

30 e repeat polymorphism in the promoter of the 5-lipoxygenase (5-LO) gene have been associated with car

31 acid (AA) into prostaglandins (PGs), whereas 5-lipoxygenase (5-LO) generates leukotrienes (LT).

32 genases (COX), and leukotrienes, produced by 5-lipoxygenase (5-LO) have been implicated in cancer pro

33 lloenzymes ribonucleotide reductase (RR) and 5-lipoxygenase (5-LO) have been investigated.

34 with the leukotriene (LT)-initiating enzyme 5-lipoxygenase (5-LO) in the MC nucleus.

35 The enzyme 5-lipoxygenase (5-LO) initiates the biosynthesis of leuk

36 The enzyme 5-lipoxygenase (5-LO) initiates the synthesis of leukotr

37 The activation of 5-lipoxygenase (5-LO) involves its calcium-dependent tra

38 5-Lipoxygenase (5-LO) is a protein widely distributed in

39 al prostaglandin E2 synthase-1 (mPGES-1) and 5-lipoxygenase (5-LO) is currently pursued as potential

40 The enzyme 5-lipoxygenase (5-LO) is key in the synthesis of leukotr

41 5-Lipoxygenase (5-LO) is the key enzyme in leukotriene b

42 5-Lipoxygenase (5-LO) is the rate-limiting enzyme in leu

43 Lipid mediators derived from 5-lipoxygenase (5-LO) metabolism can activate both pro-

44 Activation of the 5-lipoxygenase (5-LO) pathway leads to the biosynthesis

45 (cysLTs), are lipid mediators formed by the 5-lipoxygenase (5-LO) pathway of arachidonic acid metabo

46 We hypothesized that the 5-lipoxygenase (5-LO) pathway of LT metabolism plays an

47 To evaluate the role of the 5-lipoxygenase (5-LO) pathway on breast cancer growth re

48 LTs, the products of the 5-lipoxygenase (5-LO) pathway, are potent lipid mediator

49 In contrast, 5-lipoxygenase (5-LO) produces the generally proinflamma

50 lthough Alox5 expression and the presence of 5-lipoxygenase (5-LO) protein in BMDMs was observed, the

51 5-Lipoxygenase (5-LO) was the primary enzyme involved in

52 Mice that are deficient for the enzyme 5-lipoxygenase (5-LO), and therefore lack LTs, exhibit a

53 inflammatory mediator produced by the enzyme 5-lipoxygenase (5-LO), is associated with the developmen

54 ying prostaglandin E2 synthase (mPGES)-1 and 5-lipoxygenase (5-LO), key enzymes linking inflammation

55 s of cytosolic phospholipase A(2) (cPLA(2)), 5-lipoxygenase (5-LO), or 5-LO activating protein (FLAP)

56 lipid mediator of inflammation formed by the 5-lipoxygenase (5-LO)-catalyzed oxidation of arachidonic

57 Although overproduction of proinflammatory 5-lipoxygenase (5-LO)-derived leukotrienes (LTs) has bee

58 The 5-lipoxygenase (5-LO)-derived leukotrienes (LTs) influen

59 oid biosynthesis from predominantly LTB4 and 5-lipoxygenase (5-LO)-initiated pathways to LXA4, a 15-L

60 sensitized and challenged mice deficient in 5-lipoxygenase (5-LO).

61 arachidonic acid is initiated by the enzyme 5-lipoxygenase (5-LO).

62 and without a deletion of the gene encoding 5-lipoxygenase (5-LO).

63 ortant to both airway remodeling [TGF-beta1, 5-lipoxygenase (5-LO)] and airway-hyperresponsiveness (A

64 roducts of the biosynthetic crossover of the 5-lipoxygenase (5-LOX) and cyclooxygenase-2 (COX-2) path

65 Cyclooxygenase-2 (COX-2) and 5-lipoxygenase (5-LOX) enzymes are overexpressed during

66 This study shows up-regulation of 5-lipoxygenase (5-LOX) in all grades of human PanINs and

67 Potential pro-inflammatory 5-lipoxygenase (5-LOX) inhibition potential (IC50 0.76-0

68 The enzyme 5-lipoxygenase (5-LOX) initiates biosynthesis of the pro

69 s oxidized to proinflammatory eicosanoids by 5-lipoxygenase (5-LOX) on the nuclear envelope.

70 The 5-lipoxygenase (5-LOX) pathway is critical for pancreati

71 r inhibitors of the cyclooxygenase (COX) and 5-lipoxygenase (5-LOX) pathways.

72 We reported earlier that arachidonate 5-lipoxygenase (5-Lox) plays an important role in the su

73 donic acid in a 2-step reaction catalyzed by 5-lipoxygenase (5-LOX) requiring the formation of 5-HPET

74 alpha-demethylase (CYP51 or Erg11) and human 5-lipoxygenase (5-LOX) with improved potency against 5-L

75 MK-886, a functional inhibitor of the enzyme 5-lipoxygenase (5-LOX), and found increased GluR1 phosph

76 CNB-001 is a potent inhibitor of 5-lipoxygenase (5-LOX), decreases 5-LOX expression, and

77 c acid by either cyclooxygenase-2 (COX-2) or 5-lipoxygenase (5-LOX), respectively.

78 T biosynthesis is initiated by the action of 5-lipoxygenase (5-LOX), which catalyzes the transformati

79 Leukotrienes generated by 5-lipoxygenase (5-LOX)-catalyzed reaction are key regula

80 Propofol attenuated the production of 5-lipoxygenase (5-LOX)-related arachidonic acid (AA) der

81 ti-inflammatory lipoxins requires the enzyme 5-lipoxygenase (5-LOX).

82 4)) in two successive reactions catalyzed by 5-lipoxygenase (5-LOX).

83 hieved through intracellular localization of 5-lipoxygenase (5-LOX): nuclear 5-LOX favors the biosynt

84 1beta (IL-1alpha/beta(-/-)) or leukotrienes (5-lipoxygenase [5-LOX(-/-)]) produced arthritis of inter

85 ays (cyclooxygenase-2 [COX-2], celecoxib and 5-lipoxygenase [5-LOX], zileuton) added to chemotherapy

86 There it co-localizes with cPLA2alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and l

87 mediators of inflammation (cyclooxygenase 2, 5-lipoxygenase, 5-lipoxygenase-activating protein, tumor

88 We previously reported that the enzyme 5-Lipoxygenase (5LO) acts as a modulator of Abeta peptid

89 Here, we evaluated the role of 5-lipoxygenase (5LO) and its chemotactic metabolite leuk

90 T/Ei) F(2) cross and identified arachidonate 5-lipoxygenase (5LO) as a candidate gene in this region.

91 The 5-lipoxygenase (5LO) enzyme is upregulated in Alzheimer

92 transcellular biosynthesis: cells expressing 5-lipoxygenase (5LO) form LTA(4) and transfer it to cell

93 nt role for leukotriene (LT) biosynthesis by 5-lipoxygenase (5LO) in the impairment of HPV by endotox

94 5-Lipoxygenase (5LO) is a key enzyme in leukotriene (LT)

95 provide in vitro experimental evidence that 5-Lipoxygenase (5LO) is as an endogenous regulator for G

96 5-Lipoxygenase (5LO) is upregulated in Alzheimer's disea

97 The 5-lipoxygenase (5LO) produces leukotriene B(4) and 15-ep

98 arcinogenesis, but the role of hematopoietic 5-lipoxygenase (5LO) that may impact tumor immunity in d

99 5-Lipoxygenase (5LO) was recently identified as a gene t

100 5-Lipoxygenase (5LO), by producing leukotrienes, is a pr

101 stress up-regulates the ALOX5 gene product, 5-lipoxygenase (5LO), herein we investigated its role in

102 Use of T cells deficient in 5-lipoxygenase, Abcb1, and Abcc1, and comparison of the

103 mic stroke: phosphodiesterase 4D (PDE4D) and 5-lipoxygenase activating protein (ALOX5AP).

104 Although deletion of the 5-lipoxygenase activating protein (FLAP) did not influen

105 A drug discovery program in search of novel 5-lipoxygenase activating protein (FLAP) inhibitors focu

106 5-lipoxygenase activating protein (FLAP) is abundantly p

107 diovascular disease, and an inhibitor of the 5-lipoxygenase activating protein (FLAP) is in clinical

108 5-Lipoxygenase activating protein (FLAP) plays a critica

109 s showed hypoxia augmented the expression of 5-lipoxygenase activating protein (FLAP), a key enzyme i

110 e show that expression of 5-lipoxygenase and 5-lipoxygenase activating protein (FLAP), key catalytic

111 We examined expression of the 5-lipoxygenase activating protein (FLAP), which is criti

112 ists of multimers of LTC(4) synthase and the 5-lipoxygenase activating protein (FLAP).

113 ave previously reported that exposure to the 5-lipoxygenase activating protein-directed inhibitor MK8

114 genase (ALOX5) and its partner, arachidonate 5-lipoxygenase-activating protein (ALOX5AP), are involve

115 derivative 11j has an IC(50) of 4.2 nM in a 5-lipoxygenase-activating protein (FLAP) binding assay,

116 ed the mRNA expression of 5-lipoxygenase and 5-lipoxygenase-activating protein (FLAP) in human pulmon

117 n of a novel series of oxadiazole-containing 5-lipoxygenase-activating protein (FLAP) inhibitors are

118 y proteins, coactosin-like protein (CLP) and 5-lipoxygenase-activating protein (FLAP), can support 5L

119 ere it associates with its scaffold protein, 5-lipoxygenase-activating protein (FLAP), to form the co

120 ctions in this model were examined using the 5-lipoxygenase-activating protein inhibitor MK-886.

121 GSK2190915, a potent 5-lipoxygenase-activating protein inhibitor, prevents th

122 The potent and selective 5-lipoxygenase-activating protein leukotriene synthesis

123 5-Lipoxygenase-activating protein rescues activity of 5-

124 diaI infarction, including ALOX5AP (encoding 5-lipoxygenase-activating protein) associated with myoca

125 as serine proteinases, histamine 4-receptor, 5-lipoxygenase-activating protein, 15-lipoxygenase-1, pr

126 o-localizes with cPLA2alpha, 5-lipoxygenase, 5-lipoxygenase-activating protein, and leukotriene C4 sy

127 or cysLT synthesis by MK886, an inhibitor of 5-lipoxygenase-activating protein, reduced the response

128 lammation (cyclooxygenase 2, 5-lipoxygenase, 5-lipoxygenase-activating protein, tumor necrosis factor

129 re centered on the integral membrane protein 5-Lipoxygenase-Activating Protein, which we identify as

130 physiologically relevant manner with modest 5-lipoxygenase activation and formation of leukotrienes.

131 nvolving p38 and JNK MAPK, cPLA(2)alpha, and 5-lipoxygenase activation and resulting in the amplifica

132 n of soluble EMMPRIN, phospholipase A(2) and 5-lipoxygenase activities are sites for potential therap

133 in AERD may lead to dysregulated control of 5-lipoxygenase activity by PGE(2), whereas adherent plat

134 g transporters, Abcb1 and Abcc1, and through 5-lipoxygenase activity.

135 he nuclear membrane and a 2-fold increase in 5-lipoxygenase activity.

136 immunoreactive LTC(4)S protein expression or 5-lipoxygenase activity.

137 eated with recombinant adenovirus expressing 5-lipoxygenase (Ad5LO), BMPR2(+/-) mice exhibited signif

138 Genotype at rs1864414 in the arachidonate 5-lipoxygenase ALOX5 was also associated with decreased

139 e leukotriene-generating enzyme arachidonate 5-lipoxygenase (Alox5) abrogates neutrophil pro-metastat

140 from the same pathway, in which arachidonate 5-lipoxygenase (ALOX5) and its partner, arachidonate 5-l

141 of the Sp1-binding motif in the arachidonate 5-lipoxygenase (ALOX5) gene promoter (either 5/5, 5/x, o

142 Silencing of lipoxygenase pathways (5-lipoxygenase and 12/15-lipoxygenase), which are import

143 We show that expression of 5-lipoxygenase and 5-lipoxygenase activating protein (FL

144 roid cells, increased the mRNA expression of 5-lipoxygenase and 5-lipoxygenase-activating protein (FL

145 Intravenous anesthetic propofol binds to 5-lipoxygenase and attenuates leukotriene B4 production.

146 e prostanoid mediators cyclo-oxygenase-2 and 5-lipoxygenase and CC chemokine receptor antagonist Met-

147 assay systems, 10 micro m AACOCF3 inhibited 5-lipoxygenase and CoA-independent transacylase activiti

148 antinociceptive effect whereas inhibitors of 5-lipoxygenase and cyclooxygenase augmented the DOR anti

149 potential therapeutic benefits of combining 5-lipoxygenase and cyclooxygenase inhibitors for maximal

150 s subsequently metabolized by the actions of 5-lipoxygenase and cyclooxygenase to form LTC(4) and PGD

151 Roles of 5-lipoxygenase and cyclooxygenase-2 in the biosynthesis

152 its leukotriene biosynthesis in concert with 5-lipoxygenase and cytosolic phospholipase A(2)alpha act

153 It is known that 5-lipoxygenase and its product, leukotriene B4 (LTB4), a

154 tory lipid mediator generated by the enzymes 5-lipoxygenase and leukotriene A(4) hydrolase.

155 quires the sequential action of two enzymes: 5-lipoxygenase and leukotriene A(4) hydrolase.

156 -13 and the leukotriene-synthesizing enzymes 5-lipoxygenase and leukotriene-C4-synthase.

157 provide the first direct evidence that host 5-lipoxygenase and lipoxygenase products of arachidonic

158 man 5-lipoxygenase was found to be unique to 5-lipoxygenase and on a random coil.

159 ed NF-kappaB signaling, and miR-219 targeted 5-lipoxygenase and reduced leukotriene production.

160 (ROS) through a Rac1-dependent mechanism via 5-lipoxygenase and the mitochondria, leading to the biph

161 eries of bone marrow chimeras generated from 5-lipoxygenase(-/-) and leukotriene A(4) (LTA(4)) hydrol

162 whereas expression levels of MUC5AC, MUC5B, 5-lipoxygenase, and 15-lipoxygeanse 1 were similar to th

163 quential engagement of Abcb1, SP1 receptors, 5-lipoxygenase, and Abcc1 to enhance T cell migration an

164 er eicosanoid-related enzymes, namely COX-1, 5-lipoxygenase, and cytosolic phospholipase A(2) were no

165 the participation of multidrug transporters, 5-lipoxygenase, and G protein-coupled receptors for chem

166 Expression of COX-2, 5-lipoxygenase, and p-5-LOX were determined by semi-quan

167 Thus, BLT2, a unique receptor for 5-lipoxygenase- and cyclooxygenase-1-derived lipid media

168 eries of bone marrow chimeras generated from 5-lipoxygenase- and LTA(4) hydrolase-deficient mice, we

169 the utility of this approach by identifying 5-lipoxygenase as underlying previously identified quant

170 Moreover, data show that GFP-5-lipoxygenase beta-barrel containing constructs can tra

171 itory action of 47.Na occurs at the stage of 5-lipoxygenase biosynthesis as it blocks both leukotrien

172 ic residues that 1) were common to different 5-lipoxygenases but not shared with other lipoxygenases,

173 tty acids including AA activated cPLA(2) and 5-lipoxygenase by increasing [Ca(2+)](i) and inducing cP

174 However, 47.Na does not inhibit 5-lipoxygenase catalysis in a broken cell enzyme assay;

175 evated serum LTB4 and synovial expression of 5-lipoxygenase correlated with increased disease severit

176 Phosphorylation and redistribution of 5-lipoxygenase could be produced by overexpression of th

177 indicated that only the N-terminal domain of 5-lipoxygenase could carry out this translocation functi

178 sfer of autoreactive T cells from B6 mice to 5-lipoxygenase-deficient (5-LO-/-) mice, which have a fu

179 5-Lipoxygenase-deficient (5-LOX(-/-)) mice, which displa

180 expression is partially reduced in infected 5-lipoxygenase-deficient [knockout (KO)] mice.

181 Retinas from diabetic 5-lipoxygenase-deficient mice also had significantly les

182 Wild-type mice, 5-lipoxygenase-deficient mice, and 12/15-lipoxygenase-de

183 al alterations were significantly reduced in 5-lipoxygenase-deficient mice, but not 12/15-lipoxygenas

184 istopathology was significantly inhibited in 5-lipoxygenase-deficient mice, but not in 12/15-lipoxyge

185 Recent findings indicate that 5-lipoxygenase-dependent (5-LO-dependent) lipoxins regul

186 fic NADP(+)-dependent dehydrogenase utilizes 5-lipoxygenase-derived 5-hydroxy-6,8,11,14-eicosatetraen

187 ellular lipid bodies of LTC(4), the dominant 5-lipoxygenase-derived eicosanoid in eosinophils.

188 redoxin reductase, and the overexpression of 5-lipoxygenase did not inhibit thioredoxin reductase or

189 n sequence, resulting in the accumulation of 5-lipoxygenase enzyme in the cytoplasm.

190 Human genetics have implicated the 5-lipoxygenase enzyme in the pathogenesis of cardiovascu

191 Ai knockdown or pharmacological block of the 5-lipoxygenase enzyme prevented activated mast cells fro

192 e infection model of GAS in mice lacking the 5-lipoxygenase enzyme to determine the role of endogenou

193 chidonic acid can then be metabolized by the 5-lipoxygenase enzyme to generate the proinflammatory si

194 ontained both leukotriene A(4) hydrolase and 5-lipoxygenase exclusively in the cytoplasm.

195 hVPLA2 also caused the translocation of 5-lipoxygenase from the cytosol to the nuclear membrane

196 also shifts the subcellular distribution of 5-lipoxygenase from the nucleus to the cytoplasm.

197 Both sites were found to be common to 5-lipoxygenases from different species but not found on

198 A promoter polymorphism in the 5-lipoxygenase gene affects gene expression and response

199 , we hypothesized that a polymorphism in the 5-lipoxygenase gene promoter could relate to atheroscler

200 Variant 5-lipoxygenase genotypes (lacking the common allele) wer

201 Variant 5-lipoxygenase genotypes identify a subpopulation with i

202 We determined 5-lipoxygenase genotypes, carotid-artery intima-media th

203 and its cytoplasmic targets HSP25/27, LSP-1, 5-lipoxygenase, glycogen synthase, and tyrosine hydroxyl

204 from arachidonic acid through the action of 5-lipoxygenase have been known for over two decades and

205 antagonists of the type 1 cysLT receptor or 5-lipoxygenase, implying that bronchoconstriction and MC

206 required to disable nuclear accumulation of 5-lipoxygenase in all cells.

207 leukotriene A(4) hydrolase co-localizes with 5-lipoxygenase in different types of leukocytes.

208 flux, and translocation of cPLA(2)alpha and 5-lipoxygenase in eosinophils.

209 e was also found to accumulate together with 5-lipoxygenase in the nucleus of alveolar macrophages.

210 Inhibition of the LTB4 biosynthetic enzyme 5-lipoxygenase inhibited toxin A-induced increases in il

211 a) inhibit synthesis of leukotriene (through 5-lipoxygenase inhibition) or (b) block the cysLT recept

212 Before initiating therapy with the 5-lipoxygenase inhibitor or placebo, only nine of 18 ast

213 Treatment with the 5-lipoxygenase inhibitor zileuton reduced postantigen BA

214 s that were abrogated by anti-PlGF Ab or the 5-lipoxygenase inhibitor zileuton.

215 bitor, nordihydroguaiaretic acid (NDGA), the 5-lipoxygenase inhibitor, AA861, the epoxygenase inhibit

216 inhibitor; PIO+ATV and zileuton, a selective 5-lipoxygenase inhibitor; or zileuton alone.

217 5-Lipoxygenase inhibitors blocked IL-16-, eotaxin-, and

218 However, 5-lipoxygenase inhibitors, anti-IgE, and immunomodulator

219 and leukotriene C(4)) production, indicating 5-lipoxygenase inhibitory activities.

220 The enzyme 5-lipoxygenase initiates leukotriene synthesis; nuclear

221 The enzyme 5-lipoxygenase initiates the synthesis of leukotrienes f

222 5-Lipoxygenase is known to be present in the cytoplasm o

223 cium-independent phospholipase A2, 12/15 and 5-lipoxygenase) is expressed in mouse submandibular glan

224 ition of endogenous leukotriene synthesis by 5-lipoxygenase knockout in mice or by pharmacologic mean

225 Phospholipase A2/5-lipoxygenase/leukotriene-B4 (PLA2/5-LOX/LTB4) axis is

226 neonatally sensitized mice showed increased 5-lipoxygenase levels, whereas adult mice expressed more

227 A(4), an eicosanoid mediator that depends on 5-lipoxygenase (LO) for its biosynthesis, exerts a regul

228 ATP failed to decrease the parasitic load in 5-lipoxygenase (LO)-deficient macrophages.

229 19-2, we co-expressed in human macrophages a 5-lipoxygenase (LOX) 3'UTR-luciferase reporter vector to

230 alization of the key SPM biosynthetic enzyme 5-lipoxygenase (LOX) in vascular cells.

231 Thus, the predicted beta-barrel domain of 5-lipoxygenase may function like the C2 domain within pr

232 hese results indicate that nuclear import of 5-lipoxygenase may reflect the combined functional effec

233 Activation of NF-kappaB and 5-lipoxygenase-mediated (5-LO-mediated) biosynthesis of

234 , phosphorylated FTY720, or S1P also require 5-lipoxygenase-mediated synthesis of cysteinyl leukotrie

235 pe mice were enriched with receptors for the 5-lipoxygenase metabolite leukotriene B(4).

236 geted gene expression data demonstrated that 5-lipoxygenase metabolites correlated with the pathogeni

237 e results suggest that the concentrations of 5-lipoxygenase metabolites of arachidonic acid, 5-hydrox

238 y, also significant off-target reductions in 5-lipoxygenase metabolites.

239 The nuclear import of 5-lipoxygenase modulates its capacity to produce leukotr

240 tes leukotriene synthesis; nuclear import of 5-lipoxygenase modulates leukotriene synthetic capacity.

241 betic mice produced neither leukotrienes nor 5-lipoxygenase mRNA.

242 enase-activating protein rescues activity of 5-lipoxygenase mutations that delay nuclear membrane ass

243 potent chemotactic agent synthesized by the 5-lipoxygenase of neutrophils.

244 way was ineffective, whereas blocking either 5-lipoxygenase of the lipoxygenase pathway or the cycloo

245 Protein kinase A phosphorylates 5-lipoxygenase on Ser(523), and this reduces its activit

246 lipoxygenase pathway either directly through 5'-lipoxygenase or via antagonism of the leukotriene B4

247 idonic acid converted to leukotrienes by the 5-lipoxygenase pathway activated in this cell.

248 ns of proinflammatory lipid mediators of the 5-lipoxygenase pathway are significantly higher in MIAC

249 triene C(4) synthase (LTC(4)S), the terminal 5-lipoxygenase pathway enzyme that is responsible for th

250 The 5-lipoxygenase pathway has been strongly implicated in t

251 TB4 biosynthesis following activation of the 5-lipoxygenase pathway in vivo.

252 re potent lipid mediators synthesized by the 5-lipoxygenase pathway of arachidonic acid (AA) metaboli

253 The cysteinyl leukotrienes (cys-LTs) are 5-lipoxygenase pathway products implicated in asthma, in

254 Cysteinyl leukotrienes (cysLTs), 5-lipoxygenase pathway products, are recognized now not

255 east cancer cells produce metabolites of the 5-lipoxygenase pathway such as leukotriene B4 to activat

256 Here we show that by activating the 5-lipoxygenase pathway, M. tuberculosis not only inhibit

257 1 and 2 pathways and to leukotrienes via the 5-lipoxygenase pathway.

258 opose that PPARalpha in B cells and/or tumor 5-lipoxygenase pathways represents new targets for pharm

259 B(4) biosynthesis is to activate cPLA(2) and 5-lipoxygenase primarily by liberating from the outer pl

260 n of COX-2-derived prostanoids and augmented 5-lipoxygenase product formation, consistent with COX-2

261 11,14-eicosatetraenoic acid (5-oxo-ETE) is a 5-lipoxygenase product that acts via the selective OXE r

262 11,14-eicosatetraenoic acid (5-oxo-ETE) is a 5-lipoxygenase product that is a potent granulocyte chem

263 derivatives reported here identify specific 5-lipoxygenase products as candidate physiologically rel

264 LTB4 was unique among 5-lipoxygenase products in this regard, since LTD4 and 5

265 verall capacity of whole blood to synthesize 5-lipoxygenase products; these genotype-related changes

266 IL-10, suggesting a direct link between the 5-lipoxygenase proinflammatory pathway and IL-10 regulat

267 -A4 and 15-epi-LXA4 levels and for COX-2 and 5-lipoxygenase protein expression.

268 sequence that can mediate nuclear import of 5-lipoxygenase remains to be identified.

269 5-Lipoxygenase represents a novel pathway for therapeuti

270 are generated by cyclooxygenase isozymes and 5-lipoxygenase, respectively, and their biosynthesis and

271 utative bipartite nuclear import sequence of 5-lipoxygenase revealed that this region formed an alpha

272 o and in a murine model of inflammation that 5-lipoxygenase stimulation induces PPAR-alpha signaling

273 arine n-3 fatty acids (including a competing 5-lipoxygenase substrate that reduces the production of

274 nteract with the dietary intake of competing 5-lipoxygenase substrates.

275 in attenuation of GAPDH downregulation, but 5-lipoxygenase suppression had no effect.

276 umans support a proinflammatory role for the 5-lipoxygenase system.

277 ry products of arachidonic acid oxidation by 5-lipoxygenase that have been shown to be involved in re

278 hin the nuclear localization sequence-518 of 5-lipoxygenase, the ability of protein kinase A to phosp

279 enes is tightly regulated, and expression of 5-lipoxygenase, the enzyme required for the first step i

280 marrow cells from nondiabetic mice expressed 5-lipoxygenase, the enzyme required for the initiation o

281 which we identify as a scaffold protein for 5-Lipoxygenase, the initial enzyme of LT synthesis.

282 As with 5-lipoxygenase, the subcellular distribution of leukotri

283 o FLAP and subsequently being transferred to 5-lipoxygenase, thereby preventing leukotriene biosynthe

284 Unlike 5-lipoxygenase, these enzymes are expressed in most tiss

285 cell spreading stage after its oxidation by 5-lipoxygenase to leukotrienes.

286 group V sPLA(2) induced the translocation of 5-lipoxygenase to the nuclear envelope at which they wer

287 lux also promotes translocation of cytosolic 5-lipoxygenase to the nuclear membrane, a key step in th

288 include the inhibition of protein kinase C, 5-lipoxygenase, tyrosine-kinase as well as cyclooxygenas

289 Human recombinant 5-lipoxygenase used both enantiomers as substrates, and

290 Finally, 5-lipoxygenase was discovered as an additional molecular

291 n corresponding to residues 518-530 on human 5-lipoxygenase was found to be unique to 5-lipoxygenase

292 Similarly, 5-lipoxygenase was localized in the nucleus of neutrophi

293 Myocardial expression of 5-lipoxygenase was not altered by PIO, ATV, or their com

294 After adherence of neutrophils, 5-lipoxygenase was rapidly imported into the nucleus, wh

295 vealed that leukotriene A(4) hydrolase, like 5-lipoxygenase, was most abundant in the nucleus, with o

296 as well as cytosolic phospholipase A(2) and 5-lipoxygenase were markedly reduced by SB202190 in unst

297 In contrast, metabolites of 5-lipoxygenase were poor inhibitors of isolated thioredo

298 Animals lacking 5-lipoxygenase were significantly more vulnerable to int

299 ulation of two metabolic pathways (cPLA2 and 5-lipoxygenase), which results in the generation of both

300 ngly, two subpopulations of cells expressing 5-lipoxygenase with this mutated region could be discern